10/2019. UROMUNE article in BMC Infectious Diseases
The results of a clinical trial conducted with Uromune, a bacterial mucosal vaccine in sublingual spray, developed and manufactured by INMUNOTEK, have been published in BMC Infectious Diseases.
This study analyzes the effectiveness of Uromune for the treatment of uncomplicated recurrent urinary infections, a pathology that has considerable morbidity worldwide and that mainly affects women. The results, obtained in 784 patients, 648 women and 136 men, with documented urine infections by urine culture, indicate a high clinical efficacy of Uromune, confirming previous studies.
The study, carried out in two hospitals in Barcelona (Mataró Hospital and Moisés Broggi Hospital) between 2011 and 2017, concludes that UROMUNE is highly effective in reducing infectious episodes and could be the first choice treatment for the prevention of uncomplicated recurrent urinary tract infections.